Clinical Trial: An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760844) titled 'An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC' on Aug. 07.

Brief Summary: This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the LAR subtype. A total of 180 patients are planned to be enrolled.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer Triple Negative Breast Cancer (TNBC)

Intervention: DRUG: SHR- A1811+ eve

SHRA1811(HER-targeted ADC) 4.8 mg/kg, administer...